Company Analysis
Sign in

Larimar Therapeutics, Inc. (LRMR)

Nasdaq: LRMR · Pharmaceutical Preparations · Bala Cynwyd, PA · filing with the SEC since 2006
Full chart Alerts Compare
Grade6.0
◀ Past 5.6● Present 4.7▶ Future 7.5
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

55 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Larimar Therapeutics, Inc.’s names, not what it holds today.

Patents granted
55
55 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 4 in 2024 and none in 2023
Applications published
90
3 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'10'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Analysis of biological materials2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Zafgen, Inc. a former name
US, as the owner printed on each patent
48 granted
23 published
Zafgen, Inc. a former name
named as the applicant on its applications, in US
0 granted
52 published
Larimar Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
15 published
Larimar Therapeutics, Inc. its own name
US, as the owner printed on each patent
7 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 9, 202512,411,145Methods for quantifying frataxin activityAnalysis of biological materialsLarimar Therapeutics, Inc.
Aug 19, 202512,390,509Pharmaceutical composition comprising frataxin fusion protein and methods of use thereofPharmaceuticalsLarimar Therapeutics, Inc.
Jul 8, 202512,351,611Molecules for organelle-specific protein deliveryPharmaceuticalsLarimar Therapeutics, Inc.
Sep 17, 202412,091,437Molecules for organelle-specific protein deliveryPharmaceuticalsLarimar Therapeutics, Inc.
May 21, 202411,988,675Methods for quantifying frataxin activityAnalysis of biological materialsLarimar Therapeutics, Inc.
May 7, 202411,976,100Methods for treating myelin associated diseases and mitochondria associated diseasesPharmaceuticalsLarimar Therapeutics, Inc.
Feb 6, 202411,891,420Molecules for organelle-specific protein deliveryPharmaceuticalsLarimar Therapeutics, Inc.
Sep 10, 201910,406,134Methods of treating an overweight subjectPharmaceuticalsZafgen, Inc.
Apr 16, 201910,259,796Oxaspiro[2.5]octane derivatives and analogsOrganic fine chemistryZafgen, Inc.
Mar 19, 201910,231,946Methods of treating ischemic organ damage and other disordersPharmaceuticalsZafgen, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 4, 20252025/0276037METHODS OF TREATING FRIEDREICH'S ATAXIAPharmaceuticalsLarimar Therapeutics, Inc.
Mar 13, 20252025/0085297METHODS FOR QUANTIFYING FRATAXIN ACTIVITYAnalysis of biological materialsLarimar Therapeutics, Inc. · patent 12,411,145 granted from it
Mar 13, 20252025/0084136MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYPharmaceuticalsLarimar Therapeutics, Inc.
Oct 17, 20242024/0343766METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASESPharmaceuticalsLarimar Therapeutics, Inc.
Aug 1, 20242024/0254176MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYPharmaceuticalsLarimar Therapeutics, Inc. · patent 12,351,611 granted from it
Jul 11, 20242024/0228557MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYPharmaceuticalsLarimar Therapeutics, Inc. · patent 12,091,437 granted from it
May 2, 20242024/0142476FRATAXIN-SENSITIVE LIPID MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPYAnalysis of biological materialsLarimar Therapeutics, Inc.
Nov 9, 20232023/0357851FRATAXIN-SENSITIVE MARKERS FOR MONITORING FRATAXIN-REPLACEMENT THERAPYAnalysis of biological materialsLarimar Therapeutics, Inc.
Mar 2, 20232023/0061973TAT PEPTIDE BINDING PROTEINS AND USES THEREOFBiotechnologyLarimar Therapeutics, Inc.
Dec 1, 20222022/0378869USE OF FRATAXIN FOR TREATING LEIGH SYNDROME, FRENCH CANADIAN TYPEPharmaceuticalsLarimar Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Analysis of biological materials 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LRMR · research, not advice